Most heart attacks occur when a build-up of atherosclerotic plaque in the coronary arteries obstructs blood flow. SCAD has a different cause: bleeding occurs within the wall of a coronary artery, separating its layers. This can narrow the artery to such an extent that the heart muscle no longer receives enough oxygen.
People affected by SCAD often lack conventional cardiovascular risk factors, such as high cholesterol levels or significant coronary artery calcification. Around nine in ten patients are women, typically young or middle-aged adults. SCAD may account for up to a quarter of all heart attacks in women under the age of 50.
Why conservative treatment is often preferable in SCAD
Distinguishing SCAD from a conventional heart attack is crucial for treatment. In a typical heart attack, a blocked coronary artery is often reopened using a catheter-based procedure and kept open with a stent. In SCAD, however, such an intervention can cause further damage. The injured artery wall may tear further, or the bleeding within it may spread.
Another important difference is that arteries affected by SCAD often heal spontaneously. As a result, more than 80% of patients are managed conservatively without coronary intervention or coronary bypass surgery. This approach is appropriate when patients are clinically stable and blood flow to the heart is adequately maintained. Close monitoring in hospital is nevertheless essential during the first few days, when complications are most likely to occur.
Which medicines are effective?
The medical management of SCAD also differs from that of a conventional heart attack. In particular, questions remain about the use of medications that reduce blood clotting. Although these are a mainstay of treatment for conventional heart attacks, they could potentially worsen bleeding within the artery wall in patients with SCAD.
Large clinical trials establishing the safest and most effective drug treatment for SCAD are still lacking. This is the focus of the international SCAD-ALIGN-DZHK31 trial, led by researchers at the University Medical Center Hamburg-Eppendorf. This investigator-initiated academic trial is part of the Global Cardiovascular Research Funders Forum (GCRFF) multinational clinical trials initiative and is led by DZHK researchers. It is investigating the optimal intensity of antiplatelet therapy in patients with SCAD who are managed conservatively.
Why does SCAD predominantly affect women?
The reasons why SCAD occurs predominantly in women are not yet fully understood. Researchers believe that genetic susceptibility and hormonal factors may contribute. Many patients also have abnormalities in other blood vessels, particularly a condition known as fibromuscular dysplasia. This affects the structure of artery walls and can cause arteries to narrow or dilate.
Intense physical exertion and emotional stress have also been identified as potential triggers. SCAD can occur during pregnancy or after childbirth. However, the precise role of female sex hormones in the development of the condition remains unclear.
Support remains important after the artery has healed
Although affected coronary arteries often heal spontaneously, patients may continue to experience chest pain. Many also live with the fear of another heart attack. Studies show that psychological distress is common following SCAD.
The authors therefore recommend individually tailored cardiac rehabilitation, incorporating physical exercise and psychological support where needed. Physical activity is generally encouraged but should be increased gradually. Very strenuous exercise and heavy resistance training should be avoided.
The review highlights how understanding of SCAD has advanced considerably in recent years. Nevertheless, important gaps remain in our knowledge of its causes, optimal treatment and long-term consequences. International clinical trials aim to address these questions and improve care and outcomes for people affected by SCAD.
Original publication:
Bay B, Magnussen C, Adlam D, et al. Spontaneous coronary artery dissection: implications for women’s health, clinical care, and future research. The Lancet (2026).